Current Report Filing (8-k)
May 29 2019 - 1:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 29, 2019
BIOXYTRAN,
INC.
(Exact
Name if Business Issuer as specified in its Charter)
Nevada
|
|
001-35027
|
|
26-2797630
|
(State
or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification Number)
|
233 Needham Street,
Suite 300
Newton MA, 02464
|
(Address
of principal executive offices, including zip code)
|
(617)
494-1199
|
(Registrant’s
telephone number including area code)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common
|
|
BIXT
|
|
OTC Pink
|
Item 8.01.
Other Events.
On
May 29, 2019, Bioxytran issued a press release announcing that a new investor presentation is available on its website at www.bioxytraninc.com.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
By:
|
/s/ Dr. David Platt
|
|
Name:
|
Dr. David Platt
|
|
Title:
|
President and Chief Executive Officer
|
|
|
|
Dated:
May 29, 2019
|
2
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Apr 2023 to Apr 2024